← back to search

Wei Wei

Zhujiang Hospital · CN
Area of research
Hepatology · Surgery
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Cancer Immunotherapy and Biomarkers, and Cancer-related molecular mechanisms research.
h-index
33
citations
4,372
works
184
NIH funding
primary concept
Medicine
email

Recent publications

Achieving flexible fairness metrics in federated medical imaging
Nature Communications 2025cited by 13position: middledoi
An Approach for Differential Diagnosis of Breast Tumors by <scp>ctDNA</scp> Methylation Sequencing
Cancer Medicine 2025cited by 1position: middledoi
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors
International Journal of Surgery 2024cited by 31position: middledoi
Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer
International Journal of Biological Sciences 2023cited by 23position: middledoi
Establishment and validation of serum lipid-based nomogram for predicting the risk of prostate cancer
BMC Urology 2023cited by 6position: middledoi
A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score
Frontiers in Genetics 2023cited by 3position: middledoi
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
European Journal of Cancer 2022cited by 146position: middledoi
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Journal for ImmunoTherapy of Cancer 2022cited by 37position: firstdoi
One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma
BMC Medicine 2022cited by 33position: middledoi
LINC00839 promotes malignancy of liver cancer via binding FMNL2 under hypoxia
Scientific Reports 2022cited by 12position: middledoi
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
Therapeutic Advances in Medical Oncology 2021cited by 212position: middledoi
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
Frontiers in Oncology 2021cited by 123position: middledoi
Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma
JAMA Network Open 2021cited by 60position: middledoi
Comparison of the Prognostic Value of Inflammation-Based Scores in Patients with Hepatocellular Carcinoma After Anti-PD-1 Therapy
Journal of Inflammation Research 2021cited by 48position: middledoi
A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion
Hepatology International 2021cited by 40position: middledoi
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of Clinical Oncology 2020cited by 208position: middledoi
Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma
BMC Cancer 2020cited by 67position: middledoi
Lymphocyte‐C‐reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: A multicentre cohort study
Liver International 2020cited by 61position: middledoi
Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation
Cancer Medicine 2020cited by 45position: middledoi
LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling
Theranostics 2020cited by 37position: middledoi
&lt;i&gt;LYZ&lt;/i&gt; and &lt;i&gt;SST&lt;/i&gt; Prevent the Progression of Chronic Inflammation into Adenocarcinoma in the Stomach
SSRN Electronic Journal 2020cited by 0position: middledoi
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
JAMA Oncology 2019cited by 538position: middledoi
NCKAP1 improves patient outcome and inhibits cell growth by enhancing Rb1/p53 activation in hepatocellular carcinoma
Cell Death and Disease 2019cited by 47position: middledoi
Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety
Cancer Communications 2018cited by 184position: firstdoi
Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients
Journal of Gastrointestinal Surgery 2017cited by 31position: middledoi
Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts
British Journal of Cancer 2013cited by 23position: middledoi
Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
Journal of Translational Medicine 2012cited by 21position: middledoi

Grants

CAREER: Deep Learning-Enabled SERS Sensors for Next-Generation Drinking Water Monitoring
NSF2543927$550,0002026–2031PIRePORTER
POSE: Phase I: OpenLibSignal: Building a Distributed Open-Source Ecosystem for AI-Enabled Urban Systems Research
NSF2550203$298,8882026–2027PIRePORTER
ERI: Optimizing Healthcare Accessibility by Integrating Human Mobility Behaviors into Facility Planning
NSF2553462$199,9992026–2028PIRePORTER
CAREER: Harnessing Molecular Interactions and Multi-Bioinspired Toughening in Inorganic Minerals for Next-Generation Binders
NSF2554181$636,2612025–2030PIRePORTER
CAREER: Harnessing Molecular Interactions and Multi-Bioinspired Toughening in Inorganic Minerals for Next-Generation Binders
NSF2441453$636,2612025–2025PIRePORTER
Collaborative Research: SaTC 2.0: RES: A Privacy-Preserving Framework for Sharing and Learning from Scarce Medical Data
NSF2523440$405,9172025–2028PIRePORTER
NSF-SNSF: Fast and Scalable Framework for Next-Generation Very-Large-Scale Silicon Photonic Design
NSF2530406$400,0002025–2028PIRePORTER
CRII: FRR: Towards Energy-optimal Multi-Robot Navigation for Time-critical Field Tasks
NSF2452203$172,1962025–2027PIRePORTER

Frequent collaborators

Rong Guo · Tsinghua University14 papers (2012–2021)Ming Shi · Ministry of Education of the People's Republic of China8 papers (2012–2022)Jie Mei · Sun Yat-sen University7 papers (2019–2024)Shaohua Li · Jilin Agricultural University6 papers (2018–2021)Lianghe Lu · Sun Yat-sen University6 papers (2020–2021)Chong Zhong · Guangzhou University of Chinese Medicine6 papers (2012–2024)Li Xu · Jiangxi University of Traditional Chinese Medicine6 papers (2018–2022)Minshan Chen · University of Colorado Denver5 papers (2018–2022)Yihong Ling · Sun Yat-sen University5 papers (2018–2021)Minke He · Sun Yat-sen University4 papers (2019–2022)Yong‐Fa Zhang · Shantou University4 papers (2017–2020)QiJiong Li · Sun Yat-sen University4 papers (2019–2022)Anna Kan · Sun Yat-sen University4 papers (2019–2022)Jundong Li · Guangdong Polytechnic Normal University3 papers (2020–2023)ZhiCheng Lai · Sun Yat-sen University3 papers (2021–2022)Fan Yang · Southern Medical University3 papers (2020–2023)Jiahong Wang · Harbin Medical University2 papers (2021–2021)Liang-He Lu · Sun Yat-sen University2 papers (2017–2019)Xin Huang · Central South University2 papers (2020–2022)Yu-Jie Xu · Sichuan University2 papers (2021–2022)